Viewing Study NCT06420765



Ignite Creation Date: 2024-06-16 @ 11:48 AM
Last Modification Date: 2024-10-26 @ 3:30 PM
Study NCT ID: NCT06420765
Status: COMPLETED
Last Update Posted: 2024-06-17
First Post: 2024-05-14

Brief Title: A Microneurography Study of NaV18 Inhibition in Healthy Adults
Sponsor: Vertex Pharmaceuticals Incorporated
Organization: Vertex Pharmaceuticals Incorporated

Study Overview

Official Title: A Phase 1 Randomized Double-blind Placebo-controlled Parallel Study Evaluating the Effects of Single Doses of NaV18 Inhibitors on C-Nociceptor Action Potentials in Healthy Adults
Status: COMPLETED
Status Verified Date: 2024-08
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The purpose of this study is to determine the effects of Nav18 inhibition on activity-dependent slowing ADS of C-nociceptor nerve fibers evoked action potential AP conduction velocity of C-nociceptor nerve fibers using VX-150 and VX-548
Detailed Description: This clinical trial information was submitted voluntarily under the applicable law and therefore certain submission deadlines may not apply That is clinical trial information for this applicable clinical trial was submitted under section 402j4A of the Public Health Service Act and 42 CFR 1160 and is not subject to the deadlines established by sections 402j2 and 3 of the Public Health Service Act or 42 CFR 1124 and 1144

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: True
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None